DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sang Hyun Lee | - |
dc.contributor.author | I C Jeung | - |
dc.contributor.author | T W Park | - |
dc.contributor.author | Kungmin Lee | - |
dc.contributor.author | Dong Gwang Lee | - |
dc.contributor.author | Y L Cho | - |
dc.contributor.author | T S Lee | - |
dc.contributor.author | H J Na | - |
dc.contributor.author | Young-Jun Park | - |
dc.contributor.author | Hee Gu Lee | - |
dc.contributor.author | M S Jeong | - |
dc.contributor.author | Kwang-Hee Bae | - |
dc.contributor.author | Sang Chul Lee | - |
dc.contributor.author | H J Lee | - |
dc.contributor.author | Y G Kwon | - |
dc.contributor.author | H J Hong | - |
dc.contributor.author | Jang Seong Kim | - |
dc.contributor.author | Jeong Ki Min | - |
dc.date.accessioned | 2017-04-19T10:03:26Z | - |
dc.date.available | 2017-04-19T10:03:26Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | 10.18632/oncotarget.3121 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/12574 | - |
dc.description.abstract | Endostatin is an endogenous angiogenesis inhibitor that exhibits potential anti-tumor efficacy in various preclinical animal models. However, its relatively short in vivo half-life and the long-term, frequent administration of high doses limit its widespread clinical use. In this study, we evaluated whether a fusion protein of murine endostatin (mEndo) to a humanized antibody against tumor-associated glycoprotein 72 (TAG-72), which is highly expressed in several human tumor tissues including colon cancer, can extend the serum half-life and improve the anti-tumor efficacy of endostatin by targeted delivery to the tumor mass. The fusion protein (3E8-mEndo) and mEndo showed improved anti-angiogenic activity in vitro and in vivo, predominantly by interfering with pro-angiogenic signaling triggered by vascular endothelial growth factor (VEGF). Moreover, in mice treated with 3E8-mEndo, we observed a markedly prolonged serum half-life and significantly inhibited tumor growth. The improved anti-tumor activity of 3E8-mEndo can be partially explained by increased local concentration in the tumor mass due to targeted delivery of 3E8-mEndo to implanted colon tumors. Collectively, our data clearly indicate that tumor-targeting antibody fusions to endostatin are a powerful strategy that improves the poor pharmacokinetic profile and anti-tumor efficacy of endostatin. | - |
dc.publisher | Impact Journals | ko |
dc.title | Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma | - |
dc.title.alternative | Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma | - |
dc.type | Article | - |
dc.citation.title | Oncotarget | - |
dc.citation.number | 9 | - |
dc.citation.endPage | 7194 | - |
dc.citation.startPage | 7182 | - |
dc.citation.volume | 6 | - |
dc.contributor.affiliatedAuthor | Sang Hyun Lee | - |
dc.contributor.affiliatedAuthor | Kungmin Lee | - |
dc.contributor.affiliatedAuthor | Dong Gwang Lee | - |
dc.contributor.affiliatedAuthor | Young-Jun Park | - |
dc.contributor.affiliatedAuthor | Hee Gu Lee | - |
dc.contributor.affiliatedAuthor | Kwang-Hee Bae | - |
dc.contributor.affiliatedAuthor | Sang Chul Lee | - |
dc.contributor.affiliatedAuthor | Jang Seong Kim | - |
dc.contributor.affiliatedAuthor | Jeong Ki Min | - |
dc.contributor.alternativeName | 이상현 | - |
dc.contributor.alternativeName | 정인철 | - |
dc.contributor.alternativeName | 박태우 | - |
dc.contributor.alternativeName | 이경민 | - |
dc.contributor.alternativeName | 이동광 | - |
dc.contributor.alternativeName | 조영래 | - |
dc.contributor.alternativeName | 이태섭 | - |
dc.contributor.alternativeName | 나희준 | - |
dc.contributor.alternativeName | 박영준 | - |
dc.contributor.alternativeName | 이희구 | - |
dc.contributor.alternativeName | 정문식 | - |
dc.contributor.alternativeName | 배광희 | - |
dc.contributor.alternativeName | 이상철 | - |
dc.contributor.alternativeName | 이효진 | - |
dc.contributor.alternativeName | 권영근 | - |
dc.contributor.alternativeName | 홍효정 | - |
dc.contributor.alternativeName | 김장성 | - |
dc.contributor.alternativeName | 민정기 | - |
dc.identifier.bibliographicCitation | Oncotarget, vol. 6, no. 9, pp. 7182-7194 | - |
dc.identifier.doi | 10.18632/oncotarget.3121 | - |
dc.subject.keyword | Angiogenesis inhibitors | - |
dc.subject.keyword | Colorectal carcinoma | - |
dc.subject.keyword | Endostatin | - |
dc.subject.keyword | Tumor-associated glycoprotein-72 | - |
dc.subject.keyword | Vascular endothelial growth factor | - |
dc.subject.local | angiogenesis inhibitor | - |
dc.subject.local | Angiogenesis inhibitors | - |
dc.subject.local | angiogenesis inhibitors | - |
dc.subject.local | Angiogenesis inhibitor | - |
dc.subject.local | Colorectal carcinoma | - |
dc.subject.local | colorectal carcinoma | - |
dc.subject.local | Endostatin | - |
dc.subject.local | Tumor-associated glycoprotein-72 | - |
dc.subject.local | vascular endothelial growth factor | - |
dc.subject.local | Vascular endothelial growth factor (VEGF) | - |
dc.subject.local | vascular endothelial growth factor (VEGF) | - |
dc.subject.local | Vascular endothelial growth factor | - |
dc.description.journalClass | N | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.